**To the Editor:** The emergence and rapid worldwide dissemination of carbapenemase-producing bacteria (CPB), especially carbapenemase-producing *Enterobacteriaceae* (CPE), have prompted public health authorities to reconsider prevention strategies to control the spread of these organisms ([@R1]*--*[@R5]). In France, national guidelines recommend systematic screening for commensal CPE and glycopeptide-resistant enterococci (GRE) in all patients admitted to hospitals who have been hospitalized in other countries during the preceding 12 months ([@R6]*,*[@R7]) (repatriated patients), independently of whether transfer was direct from hospital to hospital (DT) or not (NDT). These guidelines also recommend implementation of presumptive patient isolation and contact precautions on admission ([@R6]*,*[@R7]). We conducted a 33-month survey at Hôpital Européen Georges Pompidou (HEGP), a university teaching hospital in Paris, of CPE and GRE in repatriated patients; we also investigated incidence of extended-spectrum β-lactamase (ESBL)--producing *Enterobacteriaceae* and carbapenemase-producing *Acinetobacter baumannii* and *Pseudomonas* spp. in the same patient group.

During November 2010--July 2013, a total of 541 patients who had previously been hospitalized in a total of 71 other countries were admitted to HEGP. Rectal swab specimens were taken from 510 patients; 82 (16.1%) were DT, 415 (81.4%) were NDT, and 13 (2.5%) had an unclear history of transfer. Median patient age was 61 (range 12--98) years; 70% of patients were male. Results of screening by using antibiotic-containing Luria Bertani broths for enrichment and plating on selective media were negative for 354 (69.4%) of the 510 patients surveyed; 33 (6.5%; 16 DT, 17 NDT) patients were colonized with [\>]{.ul}1 CPB and/or GRE and 123 (24.1%; 22 DT, 99 NDT, 2 unclear) with ESBL producers only. More specifically, 19.5% (16/82) of DT patients and 4.1% (17/415) of NDT patients were colonized with CPB and/or GRE (p\<10^−5^ by χ^2^ test); 26.8% (22/82) of DT patients and 23.9% (99/415) of NDT patients were colonized with ESBL producers only (p = 0.67). Characteristics of the 33 patients carrying CPB and/or GRE are shown in the [Table](#T1){ref-type="table"}. Of all isolates, 191 produced ESBLs only.

###### Clinical and laboratory data on 33 patients hospitalized in France who were previously hospitalized in other countries and were carrying carbapenemase-producing bacteria, glycopeptide-resistant enterococci, or both\*

  Patient no.   Year of initial hospital admission   Patient transfer status   Country of hospitalization   Species of infection   β-lactamase content   Glycopeptide resistance gene   
  ------------- ------------------------------------ ------------------------- ---------------------------- ---------------------- --------------------- ------------------------------ ---------
  ESBL          Carbapenemase                                                                                                                                                           
  1†            2010                                 DT                        Egypt                        *E. coli*              Pos                   OXA-48                         
  2†            2010                                 DT                        Thailand                     *A. baumannii*         Pos                   OXA-23                         
  3†            2010                                 DT                        Iraq                         *A. baumannii*         Neg                   OXA-23                         
                                                                                                            *E. faecium*                                                                *vanA*‡
  4             2010                                 NDT                       USA                          *E. faecium*                                                                *vanA*
  5             2011                                 NDT                       Morocco                      *K. pneumoniae*        Neg                   OXA-48                         
                                                                                                            *K. pneumoniae*        Neg                   OXA-48                         
  6†            2011                                 DT                        Senegal                      *K. pneumoniae*        Pos                   OXA-48                         
  7             2011                                 DT                        Congo                        *E. faecium*                                                                *vanA*‡
  8†            2011                                 NDT                       Benin                        *A. baumannii*         Neg                   OXA-23‡                        
  9             2011                                 NDT                       Kuwait                       *P. aeruginosa*        Neg                   VIM-2                          
  10†           2011                                 NDT                       Kuwait                       *K. pneumoniae*        Neg                   OXA-48                         
  11†           2011                                 NDT                       Kuwait                       *P. aeruginosa*        Neg                   VIM-2                          
  12†           2011                                 NDT                       Kuwait                       *E. faecium*                                                                *vanA*
  13†           2011                                 DT                        Libya                        *K. pneumoniae*        Pos                   OXA-48                         
  14†           2011                                 DT                        Libya                        *E. coli*              Pos                   OXA-48                         
                                                                                                            *K. pneumoniae*        Pos                   OXA-48                         
                                                                                                            *A. baumannii*         Neg                   OXA-23                         
                                                                                                            *E. faecium*                                                                *vanA*
  15            2011                                 NDT                       Saudi Arabia                 *E. faecium*                                                                *vanA*
  16†           2011                                 NDT                       Pakistan                     *E. faecium*                                                                *vanA*
  17            2011                                 NDT                       Italy                        *A. baumannii*         Neg                   OXA-23                         
                                                                                                            *K. pneumoniae*        Neg                   KPC-3                          
  18†           2011                                 DT                        Spain                        *K. pneumoniae*        Neg                   OXA-48                         
  19            2011                                 NDT                       Israel                       *K. pneumoniae*        Neg                   KPC-3                          
  20†           2012                                 DT                        Egypt                        *A. baumannii*         Neg                   NDM-1                          
                                                                                                            *A. baumannii*         Neg                   NDM-1                          
                                                                                                            *P. putida*            Neg                   VIM-2                          
  21†           2012                                 DT                        Tunisia                      *E. coli*              Pos                   OXA-48                         
                                                                                                            *K. pneumoniae*        Pos                   OXA-48                         
                                                                                                            *K. pneumoniae*        Neg                   OXA-48                         
  22†           2012                                 NDT                       Tunisia                      *A. baumannii*         Neg                   OXA-23                         
  23†           2012                                 DT                        India                        *E. coli*              Neg                   NDM-1                          
                                                                                                            *M. morgannii*         Pos                   NDM-1                          
                                                                                                            *P. aeruginosa*        Neg                   VIM-2                          
  24†           2012                                 NDT                       Cambodia                     *E. coli*              Neg                   NDM-4‡                         
                                                                                                            *E. coli*              Pos                   OXA-48‡                        
  25†           2012                                 DT                        Sri Lanka                    *E. coli*              Pos                   OXA-48‡                        
                                                                                                            *K. pneumoniae*        Pos                   OXA-181‡                       
  26            2013                                 NDT                       Algeria                      *E. coli*              Neg                   OXA-48                         
  27†           2013                                 NDT                       Algeria                      *E. coli*              Neg                   OXA-48                         
  28            2013                                 DT                        Tunisia                      *A. baumannii*         Neg                   NDM-1                          
  29†           2013                                 DT                        Libya                        *K. pneumoniae*        Pos                   OXA-48                         
  30            2013                                 DT                        Libya                        *K. pneumoniae*        Pos                   OXA-48                         
                                                                                                            *K. pneumoniae*        Pos                   OXA-48                         
  31            2013                                 NDT                       India                        *E. coli*              Pos                   OXA-181                        
                                                                                                            *E. coli*              Neg                   NDM-7‡                         
                                                                                                            *K. pneumoniae*        Neg                   NDM-7‡                         
  32            2013                                 NDT                       Georgia                      *P. aeruginosa*        Pos                   VIM-2‡                         
  33†           2013                                 DT                        Montenegro                   *E. faecium*                                                                *vanA*‡

\*ESBL, extended-spectrum β-lactamase; DT, direct transfer from hospital abroad to HEGP; *E. coli, Echerichia coli*; Pos, positive; *A. baumannii, Acinetobacter baumannii*; Neg, negative; *E. faecium, Enterococcus faecium*; NDT, nondirect transfer (hospitalized abroad within 12 mo before transfer to HEGP); *K. pneumoniae, Klebsiella pneumoniae*; *P. aeruginosa; Pseudomonas aeruginosa*; *P. putida, Pseudomonas putida*; *M. morganii, Morganella morganii*. †Patient carrying an ESBL producer in addition to the carbapenemase-producing bacteria and/or glycopeptide-resistant enterococci. ‡Resistance gene not reported previously in the country of initial hospitalization.

Rates of resistance for ESBL*-*producing *Enterobacteriaceae* and CPE were, respectively, 53.1% and 57.1% to gentamicin, 16.7% and 32.1% to amikacin, 77.1% and 82.1% to nalidixic acid, 63% and 75% to levofloxacin, and 70.3% and 75% to ciprofloxacin. The *Pseudomonas* spp. and *A. baumannii* isolates were also multidrug resistant; all isolates were colistin susceptible.

Among the 33 colonized patients, 13 (39.4%) were not infected; 1 of the uninfected patients died. Seven patients were infected with [\>]{.ul}1 CPB (health care--related in 2 patients, 1 of whom died), 4 patients with ESBL-producing *Enterobacteriaceae* (health care--related in 1 patient, who died), and 9 patients with other bacteria (health care--related in 4 patients, 1 of whom died). No patients were infected with GRE. Overall, 60.6% of colonized patients were infected and 12.1% died; 35% (7/20) of the infections were health care--related (3 urinary tract device--related infections, 2 cases of ventilator-associated pneumonia, 1 infection at the site of a portacath, and 1 case of cellulitis).

Almost 25% of the repatriated patients carried ESBL-producing *Enterobacteriaceae* (mostly CTX-M-15 producers; [Technical Appendix](#SD1){ref-type="local-data"}); 6.7% carried CPB and/or GRE. By comparison, during the study period, only 10.8% of 2,314 systematically screened patients in the medical and general surgery intensive care units at HEGP (repatriated patients excluded) carried ESBL-producing *Enterobacteriaceae*; 1 carried *vanA* *Enterococcus faecium* (data not shown). For patients with no record of hospitalization abroad, no CPE isolates were found; other bacterial isolates included 1 *vanA* *E. faecalis*, 13 *vanA E. faecium* (all known from previous outbreaks), 4 OXA-23--producing *A. baumannii*, and 4 VIM- and 1 IMP-producing *P. aeruginosa*.

Of the repatriated patients, 19.5% of DT patients (vs. 4.1% of NDT) and 23.9% (7 DT, 4 NDT) of those who were transferred to medical and general surgery intensive care units (ICUs) were CPB and/or GRE carriers. This finding highlights the role of severe underlying disease or injury and recent antimicrobial drug treatment. Among ICU patients, 3 died, most likely from underlying conditions, findings in line with the observation that carriage of or infection with multidrug-resistant bacteria is not the only predictor of death ([@R8]). Most of the 28 CPE isolates were resistant to fluoroquinolones and aminoglycosides except amikacin; 21 carried OXA-48--type genes, 7 of which were non-ESBL producers and were detected only around an ertapenem disk on Drigalski agar (Bio-Rad, Marnes-la-Coquette, France). All CPB, irrespective of species, showed imipenem hydrolysis in a recently described test ([@R9]) that was shortened and simplified by incubating colonies directly in antibiotic solution.

Although time-consuming and certainly perfectible, implementation of strict control measures to limit CPB and GRE spread ([@R6]*,*[@R7]) seems justified, a conclusion supported by the occurrence, since November 2010, of just 1 cross-transmission--linked CPB outbreak in an ICU at HEGP (after urgent intervention for cardiac arrest). Of particular concern is the high proportion of OXA-48--producing isolates in persons with no documented link to repatriation in France ([@R10]). This finding could be explained in part by the historical and demographic relationships between France and North Africa, where prevalence of OXA-48 is high, reflected in results from patients repatriated from that part of the continent.

###### Technical Appendix

β-lactamase profiles of multidrug-resistant Gram-negative bacilli isolated in 2010 and 2011, France.
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